Once- vs Twice-Daily Tacrolimus: Survival Rates and Side Effects: Single-Center Experience

Turunc V., Ari E., Guven B., Tabendeh B., Yildiz A.

TRANSPLANTATION PROCEEDINGS, vol.51, no.7, pp.2308-2311, 2019 (SCI-Expanded) identifier identifier identifier


Background. This study aimed to determine whether de novo, prolonged-release tacrolimus- (PR-tacro) based immunosuppressive regimen affected graft and patient survival when compared to an immediate-release, twice-daily, tacrolimus- (IR-tacro) based regimen in kidney transplant recipients. We also aimed to determine the difference between the frequency of side effects, including diabetes control, in study groups.